Living Cell Technologies Ltd. (AU:1AI)
ASX:1AI
Want to see AU:1AI full AI Analyst Report?
1AI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume31.97M
Average Volume (3M)2.98M
Market Cap
AU$24.28M
Enterprise ValueAU$18.57M
Total Cash (Recent Filing)AU$1.88M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,023,570,200
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure meaningfully lowers fixed financing costs and reduces bankruptcy risk during lengthy clinical development cycles. This durable financial resilience improves the company’s ability to reach clinical milestones before mandatory debt servicing, helping preserve cash for R&D or strategic partnering.
Improving Loss TrajectoryMaterial narrowing of net losses and reduced cash burn in the most recent year signals better cost control and operational execution. If sustained, this extends the firm’s runway, reduces the size and frequency of future financings, and raises the probability of advancing clinical programs to value-driving milestones.
Specialized Clinical PlatformA focused, clinical-stage encapsulated cell-therapy platform represents a durable competitive position: specialized IP, high technical barriers, and differentiated science. Clinical progress can unlock partnerships or licensing, providing a structural path to commercialisation without current revenue.
Bears Say
No Meaningful RevenueAbsence of recurring commercial revenue means the enterprise cannot self-fund development and is structurally reliant on external capital or partnerships. This persistent revenue gap lengthens the path to sustainability, increases execution risk, and heightens sensitivity to financing market access over the medium term.
Consistent Negative Cash FlowContinued negative operating and free cash flow across reporting years is a structural weakness that forces repeated fundraising, dilutes equity, and constrains investment in parallel programs. It reduces strategic optionality and may delay or compress R&D timelines if capital is scarce.
Eroding Equity And AssetsDeclining shareholders’ equity and a shrinking asset base reflect cumulative losses that erode financial flexibility and collateral value. This makes non-dilutive financing harder to obtain, raises the cost of capital, and limits the company’s ability to scale or pivot programs without dilutive equity issuance or partnership concessions.
Living Cell Technologies News
1AI FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Living Cell Technologies Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is AU$24.28M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 80 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Feb 27, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 2,023,570,200 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:1AI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-49.25%
Trailing 12-Months
Asset Growth
-15.04%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
Technical Analysis
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Options Prices
Currently, No data available
---